Scholarlink

<p>While variant <i>TP53</i> is an adverse prognosis factor in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), current clinical prognosis and variation feature analysis of <i>TP53</i> alterations remain limited. We evaluated 333 MDS/AML patients with <i>TP53</i> mutations, single nucleotide polymorphisms (SNPs), and wild-type <i>TP53</i> to characterize clinical features and identify prognostic factors using next-generation sequencing (NGS) data. Interpretation requires caution due to sample size limitations, particularly in subgroup analyses. Multivariate analysis identified age, gender, cytogenetic risk, transplantation, white blood cell (WBC) count, <i>TP53</i> status, and <i>TP53</i> variant allele frequency (VAF) &gt; 40% as independent prognostic factors. Patients with <i>TP53</i> mutations (<i>n</i> = 45) had significantly worse overall survival (OS) and disease-free survival (DFS) (2-year OS: 34.94%; DFS: 38.26%) compared to those with <i>TP53</i> SNPs (<i>n</i> = 84; 2-year OS: 77.25%; DFS: 87.54%; <i>P</i> &lt; 0.001) and <i>TP53</i> wild-type patients (<i>n</i> = 204; 2-year OS: 63.25%; DFS: 70.72%; <i>P</i> &lt; 0.05). Notably, <i>TP53</i> SNP carriers exhibited comparable or superior survival to <i>TP53</i> wild-type patients. Focusing on the <i>TP53</i> mutated cases, we identified <i>TET2</i> as a possible disadvantageous prognosis factor among the coexistent gene mutations of <i>TP53</i>, suggesting that a potential dual-gene (<i>TET2</i>-<i>TP53</i>) mutation signature is associated with shorter survival. Therapeutic analysis revealed that transplantation improved survival in <i>TP53</i> variant patients compared to chemotherapy alone, supporting its role as an effective intervention. Our findings highlight the prognostic significance of <i>TP53</i> alterations in MDS/AML and underscore the importance of karyotype risk stratification, post-transplant relapse prevention, and mutation monitoring to optimize outcomes. Future studies with larger cohorts are needed to validate these results.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月28日

查看全文
  • Xiaodi Yang,
  • Zeyin Liang,
  • Li Ji,
  • Wei Liu,
  • Bingjie Wang,
  • Yuan Li,
  • Jinping Ou,
  • Xinan Cen,
  • Hanyun Ren,
  • Stefan Wuchty,
  • Ziding Zhang,
  • Yujun Dong

摘要

While variant TP53 is an adverse prognosis factor in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), current clinical prognosis and variation feature analysis of TP53 alterations remain limited. We evaluated 333 MDS/AML patients with TP53 mutations, single nucleotide polymorphisms (SNPs), and wild-type TP53 to characterize clinical features and identify prognostic factors using next-generation sequencing (NGS) data. Interpretation requires caution due to sample size limitations, particularly in subgroup analyses. Multivariate analysis identified age, gender, cytogenetic risk, transplantation, white blood cell (WBC) count, TP53 status, and TP53 variant allele frequency (VAF) > 40% as independent prognostic factors. Patients with TP53 mutations (n = 45) had significantly worse overall survival (OS) and disease-free survival (DFS) (2-year OS: 34.94%; DFS: 38.26%) compared to those with TP53 SNPs (n = 84; 2-year OS: 77.25%; DFS: 87.54%; P < 0.001) and TP53 wild-type patients (n = 204; 2-year OS: 63.25%; DFS: 70.72%; P < 0.05). Notably, TP53 SNP carriers exhibited comparable or superior survival to TP53 wild-type patients. Focusing on the TP53 mutated cases, we identified TET2 as a possible disadvantageous prognosis factor among the coexistent gene mutations of TP53, suggesting that a potential dual-gene (TET2-TP53) mutation signature is associated with shorter survival. Therapeutic analysis revealed that transplantation improved survival in TP53 variant patients compared to chemotherapy alone, supporting its role as an effective intervention. Our findings highlight the prognostic significance of TP53 alterations in MDS/AML and underscore the importance of karyotype risk stratification, post-transplant relapse prevention, and mutation monitoring to optimize outcomes. Future studies with larger cohorts are needed to validate these results.